Merck Says Province Of Saskatchewan Adds CAPVAXIVE, 21-Valent Pneumococcal Conjugate Vaccine, To Publicly Funded Adult Immunization Program

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the province of Saskatchewan has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to its publicly funded adult immunization program. This addition supports increased access to pneumococcal immunization for eligible adults in accordance with the provincial eligibility criteria.